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ABSTRACT 
Objective: 
Determine modifiable social and psychological health factors that are associated with use of oral opioid 
and non-opioid medications for OA. 
Methods: 
Patients were categorized based on use of the following oral medications: opioids (with/without other 
oral analgesic treatments), non-opioid analgesics, and no oral analgesic treatment.  We used 
multinomial logistic regression models to estimate adjusted relative risk ratios (RRRs) of using an opioid 
or a non-opioid analgesic (vs. no oral analgesic treatment), comparing patients by levels of social 
support (Medical Outcomes Study scale), health literacy (“How confident are you filling out medical 
forms by yourself?”), and depressive symptoms (Patient Health Questionnaire-8). Models were adjusted 
for demographic and clinical characteristics.  
Results: 
In this sample (mean age 64.2 years, 23.6% women), 30.6% (n=110) reported taking opioid analgesics for 
OA, 54.2% (n=195) reported non-opioid use, and 15.3% (n=55) reported no oral analgesic use. Opioid 
users had lower mean social support scores (10.0 vs. 10.5 vs. 11.9, p=0.007) and were more likely to 
have moderate-severe depressive symptoms (42.7% vs. 24.1% vs. 14.5%, p<0.001). Health literacy did 
not differ by treatment group type.  Having moderate-severe depression was associated with higher risk 
of opioid analgesic use compared to no oral analgesic use (RRR 3.24, 95%CI 1.20, 8.73) when adjusted 
for sociodemographic and clinical factors.  Neither social support nor health literacy was associated with 
opioid or non-opioid oral analgesic use in fully adjusted models. 
Conclusions:  
Knee OA patients with more severe depression symptoms, compared to those without, were more likely 
to report using opioid analgesics for OA.   
 
Keywords: osteoarthritis, knee osteoarthritis, treatment, utilization, depression, social support, health 
literacy  
INTRODUCTION 
The American College of Rheumatology (ACR), the Osteoarthritis Research Society International 
(OARSI), and other professional organizations have developed recommendations for the management of 
knee OA1, 2.  Oral pharmacologic therapies are recommended for the initial management of patients 
with knee OA, including acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and 
cyclooxygenase-2 (COX-2) selective inhibitors.  Opioid analgesics are also recommended in patients who 
have failed conservative medical therapy and in patients unwilling to undergo or have contraindications 
for joint replacement surgery.   
These ACR- and OARSI- recommended treatments are based on the “best available evidence” of 
benefit and safety of pharmacologic agents and the consensus of clinical experts from a wide range of 
disciplines1, 2.  However, both also acknowledge that these medications are associated with certain 
adverse effects.  For instance, there are concerns about iatrogenic opioid addiction, opioid-induced 
hyperalgesia, and opioid-induced decreases in quality of life3.  OA management may need to be tailored 
based on patients’ medical history, comorbidities, social history, and treatment preferences.     
 Identifying the determinants of OA pharmacologic treatment use may allow better 
understanding of how patients may choose among the various oral pharmacologic options for knee OA.  
Traditional models of health service utilization typically include what Andersen has termed 
“predisposing,” “enabling,” and “need” factors as determinants of treatment use (Figure 1)4.  
Predisposing factors include biological factors that increase the likelihood of needing care, social 
statuses that influence individuals’ access to care and ability to cope (e.g., education, income), and 
people’s health beliefs.  Enabling factors facilitate access to services (e.g., health insurance coverage).  
Need factors refer to the unpleasantness of individuals’ symptoms and beliefs about the causes and 
seriousness of symptoms.  Previous OA studies have examined many of these determinants of OA 
treatment use.  Younger age5-7, female sex6, 8-11,  higher educational attainment5, 7, 9, having medical 
insurance9, greater OA disease severity5-7, 11, and higher number of comorbidities7-9 have all been 
associated with increased use of various oral pharmacologic treatments for OA.   
Despite the number of factors that are identified in Andersen’s model of medical 
service/treatment utilization, the model has generally overlooked the important effects of individuals’ 
social and psychological health4, 12.  These health factors may influence perceptions of need and use of 
medical treatments.  The extent and quality of social relationships can serve as an enabling resource to 
facilitate or impede use of treatments4, 13-15.  In a cohort of primary care patients with OA, though, 
having low level of social support was strongly associated with increased clinic visits that may translate 
to more receipt of medication prescriptions16.  Psychological characteristics considered as predisposing 
variables to use of treatments include cognitive impairment4, 17  and mood disorders, such as depression 
and anxiety18-21.  Arthritis patients with limited health literacy may make greater use of health services 
and treatments designed to treat (rather than prevent) disease complications, including analgesic 
medications22.  A literature review concluded that OA patients with anxiety and depression took more 
analgesic medications than other OA patients without these comorbidities23.  The association of these 
social and psychological health factors with the utilization of an oral opioid agent instead of a non-opioid 
analgesic or no oral analgesic treatment at all for OA is unknown, however.   
Of utmost importance, while many of the known determinants of OA treatment use are 
relatively fixed, several social and psychological health factors are modifiable at the point of care24.  
Quality of social relationships, psychological/personality dispositions, and other psychosocial risk factors 
may all be targeted24, 25.  Health literacy can be improved through provision of information, effective 
communication, and structured education26.  The primary objective of this study was to determine 
which potentially modifiable social and psychological health factors are associated with use of various 
oral analgesic treatments in a sample of patients with chronic knee pain due to OA.  We hypothesized 
that lower levels of social support, inadequate health literacy, and higher levels of depression would all 
be associated with increased use of opioid analgesic versus non-opioid and no oral analgesic treatment 
use.   
METHODS 
 
Study design and setting  
 This study is a cross-sectional analysis of baseline data from a clinical trial.  The study sample 
includes participants of a clinical trial of a positive psychological intervention on pain among individuals 
with symptomatic knee OA recruited from two large, urban, academic Veterans Affairs (VA) medical 
centers 27.  Details of the study design and protocol have been described previously27.  Briefly, 180 
African American and 180 white primary care patients with chronic pain from knee OA were randomized 
to a six-week program of either positive psychological skill building-activities or neutral control activities.  
Patients who met study criteria were invited to complete a baseline questionnaire administered by 
trained research staff.  The study was approved by the VA Central Institutional Review Board.   
Participants 
 Patients who met the  following criteria based on a review of VA electronic medical records 
were mailed an invitation to be screened for the study:  non-deceased; non-Hispanic African American 
or white race; 50 years or older; had a primary care visit at a participating site in the past 12 months; 
had a diagnosis of OA (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-
9-CM] code 715); and did not have a diagnosis of a rheumatologic disease associated with inflammatory 
arthritis (rheumatoid arthritis, lupus, psoriatic arthritis, or ankylosing spondylitis) or Alzheimer’s 
disease/dementia based on ICD-9-CM codes. Patients who expressed interest or did not respond within 
two weeks were called over the telephone by research staff to determine study eligibility prior to 
enrollment.   
Individuals were included in the study if they were ≥50 years of age; received primary care at a 
participating site; self-reported as non-Hispanic African American or white; had frequent pain 
characteristic of symptomatic knee OA identified using questions from the Osteoarthritis Initiative 
study28; rated their pain ≥4 on a 0-10  numerical rating scale; and could speak, read, and write in English.  
Exclusion criteria included self-reported serious problems with hearing, eyesight, or memory; diagnosed 
with any type of arthritis other than OA; treated for cancer in the last 3 years; had a steroid injection or 
knee replacement in the past 3 months; planned to have a knee replacement in the next 6 months; self-
reported inability to complete the study procedures (i.e., telephone calls and program activities that 
involve reading and writing); lacked a reliable telephone number; and answered ≥2 items incorrectly on 
a 6-item screening for cognitive impairment29. 
Study variables 
Outcome 
 Current use of the following oral pharmacologic treatments for knee OA was assessed at 
baseline:  acetaminophen, NSAIDs, COX-2 inhibitors, and opioid medications.  Treatment use was 
assessed based on self-report with dichotomous variables indicating use or not of each of the OA 
medication of interest.  The question was asked: “Do you currently use any of the following medications 
for joint pain or arthritis?”  For this study, patients were grouped into three categories of analgesic use: 
oral opioids (with or without other oral analgesic treatments), oral non-opioid analgesics, and no oral 
analgesic use.   
Exposure Variables 
 Social support was assessed using a 4-item abbreviated version of the Medical Outcomes Study 
social support scale that represents four dimensions of social support:  emotional/informational, 
tangible, affectionate, and positive social interaction30.  The sum of responses to all items constitute the 
overall social support score.  Score range is from 0-16, with a higher score indicating more social 
support.  
 Health literacy was assessed by the question, “How confident are you filling out medical forms 
by yourself?”  This is the best single question to detect patients with inadequate or marginal health 
literacy31.  The responses were dichotomized to those with adequate (“extremely”, “quite a bit”) and 
inadequate (“somewhat”, “a little bit”, “not at all”) health literacy.  Level of depression was assessed 
using the Patient Health Questionnaire (PHQ-8), which assesses the Diagnostic and Statistical Manual of 
Mental Disorders-IV criteria for the diagnosis of depressive disorders32.  PHQ-8 scores (range: 0-24) were 
used to differentiate between those with none-minimal (0-4), mild (5-9), moderate (10-14) and severe 
(≥15) depressive symptoms32.   
Covariates 
 Demographic characteristics that were obtained included: age, sex, race, education (≤ high 
school/general education equivalency diploma, some college or 2-year degree, ≥ 4-year college degree), 
annual income (<$20,000, $20,000-39,999, ≥$40,000), and current marital status (married/living with 
partner or not). 
 Clinical data that were collected included self-rated health (excellent, good, fair, poor) and body 
mass index (BMI).  OA-related disease severity was assessed using the Western Ontario McMaster 
Universities Osteoarthritis Index (WOMAC)33.  Comorbid medical conditions were assessed using an 
interviewer-administered version of the Charlson Comorbidity Index34.  BMI was assessed via chart 
review, and all else were assessed via patient-reported surveys.  
Statistical analysis 
 Descriptive statistics, including means and standard deviations (SD) for continuous variables and 
frequencies and percentages for categorical variables, were calculated.  Demographic, clinical, social 
health, and psychological health variables were compared by type of oral OA analgesic group using 
analysis of variance (ANOVA) tests for continuous variables and Pearson’s χ2 tests for categorical 
variables.   
Multinomial logistic regression models were used to estimate the unadjusted and adjusted 
relative risk ratios (RRRs) of using oral opioid or non-opioid analgesic (vs. no oral analgesic treatment), 
comparing patients by levels of social support, health literacy, and depressive symptoms.  Relative risk 
was obtained by exponentiating the linear equations derived from each model, yielding regression 
coefficients that are relative risk ratios for a unit change in each exposure variable of interest35.  
Separate models were used to estimate the unadjusted and adjusted RRRs of using oral opioid versus 
non-opioid analgesic, also comparing patients by the different exposure variables.  Models were 
adjusted for age, sex, race, income, WOMAC , comorbidity, and BMI.  Only variables that were 
previously associated with the outcome5-11 and exposure variables and that do not lay in the causal 
pathway were considered as covariates.  Self-rated health and marital status were also considered as 
covariates but were removed from the models due to high correlation (│correlation coefficient│ ≥ 0.33) 
with other variables (comorbidity index and social support scores, respectively).  All covariates were 
tested for collinearity using the same methodology.  Fully adjusted models included all covariates and all 
exposure variables.    
 
  
RESULTS 
  Among 5,111 who were mailed an invitation to participate in the study and 67 who responded 
to the study brochures, 839 were screened for study eligibility (Supplement 1).  While 351 did not meet 
the study inclusion criteria, 488 were found to be eligible.  Among the eligible participants, 128 could 
not be further contacted or chose not to participate in the study.  Their demographic characteristics and 
mean pain level were not significantly different from those who entered the study (data not shown). 
A total of 360 veterans with symptomatic knee OA were included in the study (Table 1).  Mean 
age was 64.2 years, and 23.6% were women.  By study design, 50% identified as non-Hispanic white and 
50% identified as African-American.  The majority had an annual income of <$40,000 (59.9%) and were 
not married/living with a partner (54.3%).  Most (60.6%) reported having good or better health, and 
mean calculated BMI was 31.8.  Mean WOMAC total score was 48.0.   
Nearly a third (30.6%) reported using an oral opioid analgesic, with or without other oral 
analgesic medications.  The majority of patients (54.2%) reported currently using a non-opioid oral 
analgesic for knee OA, such as acetaminophen, a NSAID, and/or a COX-2 inhibitor (Table 2).  Only 15.3% 
of participants were not using any oral medication for knee OA.  
Demographic and Clinical Characteristics by OA Treatment Use 
 Patients using opioids, in comparison to those using non-opioid analgesics and those not using 
any oral analgesic, had a lower mean age (62.5 vs. 64.3 vs. 67.1, respectively, p=0.006).  Mean age by 
oral analgesic use group differed by only a few years, however.  Opioid analgesic users, compared to the 
two other OA oral analgesic groups, were also much more likely to report having fair/poor instead of 
good/excellent health (58.2% vs. 32.3% vs. 27.3%, p<0.001) and to have ≥4 comorbidity index scores 
(44.5% vs. 33.3% vs. 38.2%, p=0.028).  Opioid analgesic users also had significantly higher mean WOMAC 
total score compared to the other treatment groups (54.5 vs. 45.7 vs. 42.7, p<0.001).  No other 
demographic or clinical characteristics differed across OA treatment groups (Table 1).  
Social and Psychological Factors by OA Treatment Use 
 Mean social support score was lower among opioid analgesic users, compared to non-opioid 
medication and no oral medication users (10.0 vs. 10.5 vs. 11.9, p=0.017); mean scores differed by just a 
few points, however.  More than three quarters of participants had adequate health literacy. Adequate 
health literacy level was more often observed among non-oral analgesic users than others, but health 
literacy level did not significantly differ by OA treatment group (Table 1).  Having moderate to severe 
depressive symptoms was most common among opioid analgesic users (42.7% vs. 24.1% among non-
opioid analgesic users vs. 14.5% among those not taking oral analgesics, p<0.001). There was a three-
fold difference between opioid and non-oral analgesic users and almost a two-fold difference between 
non-opioid and non-oral analgesic users.    
Association of Social/Psychological Health with OA Treatment Use  
 Table 3 shows the associations between the social and psychological health measures with oral 
analgesic use, unadjusted and adjusted for age, sex, race, income, WOMAC total score, comorbidity 
score, and BMI.  Having a higher social support score was modestly but significantly associated with 
lower risk of non-opioid and opioid oral analgesic versus no oral analgesic use (unadjusted RRR 0.91, 
95%CI 0.83-0.99, and 0.88, 95%CI 0.80-0.96, respectively).  The effect estimate for the association 
between social support and lower risk of oral non-opioid versus no oral analgesic use was nearly 
identical but no longer statistically significant when adjusted for patient sociodemographic and clinical 
characteristics.  The association between social support and lower risk of oral opioid versus no oral 
analgesic use was slightly reduced and remained statistically significant when adjusted for the same 
characteristics (adjusted RRR 0.90, 95%CI 0.82-1.00).  In a fully adjusted model that included all 
covariates and other exposure variables, the RRRs for social support were further reduced and not 
significantly associated with oral opioid or non-opioid analgesic use.  There was no statistically 
significant association between health literacy and type of oral analgesic use in the unadjusted or 
adjusted models (Table 3).  . 
Having moderate-severe depressive symptoms was strongly associated with higher risk of oral 
opioid analgesic use compared to no oral analgesic and oral non-opioid analgesic use (unadjusted RRR 
4.38, 95%CI 1.89-10.15 and 2.35, 95%CI 1.42-3.87, respectively).  The effect estimate for the association 
between depression symptoms and oral opioid analgesic versus no oral analgesic use was reduced but 
remained statistically significant when adjusted for age, sex, race, income, WOMAC total score, 
comorbidity score, and BMI (adjusted RRR 3.24, 95% CI 1.20-8.73). This estimate was further reduced 
and remained statistically significant when additionally adjusted for health literacy and social support 
(fully adjusted RRR 2.96, 95%CI 1.08-8.07).  The effect estimate for the association between depression 
symptoms and oral opioid versus oral non-opioid analgesic use was attenuated and was no longer 
statistically significant when adjusted for sociodemographic and clinical variables.  In the fully adjusted 
model, the estimate minimally changed.  The severity of depression symptoms was not statistically 
significantly associated with non-opioid oral medication use compared to no oral analgesic medication 
use in the unadjusted or adjusted models.   
   
DISCUSSION 
In this cohort of patients with knee OA, we found that nearly a third of the patients used oral 
opioid analgesics to treat their knee OA symptoms.  A majority of the patients used non-opioid oral 
analgesics.  Our study showed that having moderate to severe depressive symptoms was independently 
associated with oral opioid analgesic use compared to no oral analgesic use among those with 
symptomatic knee OA.  In addition, we found that opioid medication users reported the lowest level of 
social support.  However, social support did not have a statistically significant association with oral 
analgesic use in OA management in our adjusted models.  We also found that health literacy did not 
have a statistically significant association with OA treatment use.   
 Our study is the first to show an association between depression and oral opioid analgesic use 
among knee OA patients, independent of sociodemographic and clinical health factors.  Previous cohort 
studies and population surveys suggest that patients with non-cancer pain with a coexisting mental 
health condition (e.g., mood or personality disorder) are more likely to receive opioids than those with 
similar pain level but without a mental health condition18-21.  OA studies also reported that depression 
and anxiety contribute to increased hospitalization and utilization of healthcare providers16, 36.  In a 
study of women with physical disability, mostly due to OA, higher level of depression was associated 
with using a maximum dose of any analgesic medication37.   
 Why depression is linked to increased oral opioid medication use is unclear, but there are 
various potential explanations.  Mental health conditions, such as depression, may lower the pain 
threshold and diminish responsiveness to opioids in patients with OA38, 39.  Individuals with mood 
disorder may be using opioids to “self-medicate” their emotional pain and its associated physical 
symptoms40.  Those with mental health disease may be more likely to seek opioids for misuse than 
others18.  Healthcare providers may also be more likely to prescribe opioids to those with mental health 
conditions who tend to have multiple clinical comorbidities 20.   
In addition, there is substantial evidence that depressive symptoms are predictive of elevations 
in pain, including arthritis-related pain41, 42.  Depressive symptoms are also associated with greater odds 
of inadequate pain relief in knee OA43.  While non-opioid analgesics are often the first-line medications 
used for the pharmacologic treatment of OA, depressive symptoms may reduce the response to initial 
pharmacologic treatments42, 43.  Consequently, those with more depressive symptoms are more likely to 
require second-line medications, including opioids.  Conversely, those who are on opioids may be more 
likely to develop depressive symptoms than those who are not on opioids.  It has been demonstrated in 
a large retrospective cohort study that opioid users have an up to two-fold increased risk of future 
depressive symptoms than opioid non-users44.  Establishing a cause-effect relationship requires 
prospective studies.  
   Finding a significant association between depressive symptoms and opioid treatment use has 
important clinical implications.  Educating healthcare providers about timely identification of mood 
disorders among those with OA may potentially minimize opioid dependence of patients living with this 
comorbidity.  Implementation of screening questionnaires can help identify this psychological 
comorbidity at an early stage, which could lead to the early implementation of a management plan to 
improve the outcomes of patients with OA23.  Implementing an anti-depressant therapy (e.g., 
duloxetine) in tandem with a NSAID or other non-opioid analgesics may also be appropriate1.  As opioid 
use may also exacerbate depression44, OA patients who are prescribed opioids for pain must be followed 
very closely with ongoing assessment of benefits and risks, including the development or worsening of 
depressive symptoms.  From a research standpoint, evaluating the effects of pharmacologic and non-
pharmacologic treatments for depression on the utilization of opioid versus non-opioid analgesic use for 
OA would be an appropriate next step.     
 Our study adds to the literature by reporting no statistically significant association between 
health literacy and OA medication use.  Evidence on the relationship between health literacy and 
healthcare service and rheumatologic treatment utilization is limited.  Low health literacy often results 
in more frequent physician visits, non-physician clinic visits, and hospital admissions22, 45.  This suggests 
that those with limited health literacy, compared to those with adequate or high health literacy, may be 
more likely to receive a prescription for and use pharmacologic treatments, such as analgesic 
medications.   
Our study results also showed that among those with knee OA, opioid medication users, in 
comparison to non-opioid medication users, had the lowest levels of social support.  Among OA patients 
in Germany, living alone was the strongest factor associated with increased visits to a general 
practitioner16.  Social support has distress-alleviating and stress-buffering effects46.  Social support may 
act as a “buffer” to mitigate the severity of the disease, reducing the need for treatment.  High social 
support has, in fact, been linked to decreased need of particular health services, such as nursing care 
and mental health service15, 47.  However, supportive social networks may also contribute to increase in 
general medical service use47.  Being married, a structural measure of social support, has been 
associated with increased use of COX-2 inhibitors in a survey of community-dwelling adults with 
arthritis9.  Our observed association between social support and oral OA treatment use was no longer 
statistically significant when adjusted for various demographic, clinical, and psychological factors.  It is 
possible that these other factors, compared to social factors, may be more relevant determinants of OA 
oral analgesic treatment use.    
Greater social support has been associated with higher physical functioning, general health, 
mental health, and vitality among those with OA48.  Social support is also known to moderate the effects 
of pain, functional limitation, and depression in older adults with OA49.  Interventions that promote 
social support by improving the quality of social relationships, especially those that strengthen ties with 
confidants, should be developed25.  The effects of such interventions to the utilization of opioid versus 
non-opioid analgesic treatment for OA should also be tested.    
Consistent with previous OA studies5-9, 11, we found that opioid medication users had worse self-
rated health, more clinical comorbidities, and more OA-related symptoms that opioid non-users.  
Increased number of co-morbidities has been positively associated with use of or prescription receipt for 
oral COX-2 selective NSAIDs and opioid agents for lower extremity OA7-9.  Greater OA disease severity  
has also been associated with more oral prescription analgesic use for OA5-7, 11.  While greater OA 
disease severity may predict increased use of opioid medications, it is also possible the opioid use may 
worsen OA symptoms.  Many of these OA studies5-9 have a cross-sectional study design, and longitudinal 
studies are necessary to clarify this relationship.   
We also found that opioid medication users were the youngest in our cohort.  Consistent with 
the literature, younger age is often associated with use of any oral analgesic, NSAIDs and opioid 
medications among OA patients5-7.  Sex, race, and income did not vary across OA oral treatment groups 
in our cohort.  In contrast, female sex has been previously, but inconsistently, associated with increased 
use of any oral analgesic for OA5-11, and White OA patients are prescribed COX-2 selective NSAIDs and 
opioid analgesics5, 8 more often than their African-American counterparts.    Low income is usually 
associated with current use of opioids but with decreased use of NSAIDs6, 9.  Inconsistencies between 
our findings and these other studies may be related to the fact that we examined clinical trial 
participants.  Patients who participate in clinical trials often have different risk profiles compared with 
the broader population.  Lack of association between a demographic characteristic and OA oral 
treatment use may be due to variations in the patient populations being studied. 
There are several limitations to consider in interpreting our findings.  First, we conducted a 
cross-sectional analysis of baseline data. Therefore, causal relationships cannot be ascertained.  We 
cannot ascertain if depression causes an increase in oral opioid medication use, if opioid medication use 
leads to more symptoms of depression, or if treatment-resistant OA leads to either or both depression 
and use of opioids.  Second, oral medication use was self-reported, which is susceptible to recall bias.  
However, questionnaires which measure medication use behaviors generally exhibit high concordance 
with non self-report methods50.  In addition, medication use was assessed by a dichotomous variable, 
and does not provide more detailed information, such as the frequency and quantity of medication use.  
Third, we recruited research participants from a single state, and the generalizability of our study 
findings among knee OA patients living in other regions is unclear.  Fourth, while we screened out those 
who were treated for cancer in the last 3 years, we did not inquire about any recent surgical procedure 
or other medical conditions that might have necessitated oral analgesic treatment use.  Some may have 
reported oral analgesic treatment use for indications other than joint pain even though our treatment 
use question specifically asked for use of a medication for joint pain or arthritis.   
  
CONCLUSIONS 
 Our study is the first to examine the association between psychological and social health factors 
and the use of different types of oral analgesics for knee OA.  While nearly a third of the patients used 
oral opioid analgesics, the majority used only non-opioid oral analgesics to treat their knee OA 
symptoms.  Our results showed that opioid analgesic users, compared to others, were more like to have 
moderate to severe depressive symptoms and lower social support.  Higher level of depression  was 
independently associated with opioid analgesic use versus no oral analgesic use.  Although further 
investigation using longitudinal data is needed, these cross-sectional findings underscore the need to 
pay attention to mental health issues in the management of patients with symptomatic knee OA.   
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TABLES 
Table 1.  Sociodemographic, clinical and psychosocial characteristics among oral opioid analgesic users versus oral non-opioid 
analgesic users vs. those not using any oral analgesic medication 
 
All 
(N=360) 
Opioid usersa 
(N=110) 
Non-opioid 
analgesic users 
only 
(N=195) 
Non-oral 
analgesic users 
(N=55) p-valueb 
Demographic 
Age, M (SD) 64.2 (8.8) 62.5 (8.1) 64.3 (8.8) 67.1 (9.2) 0.006 
Female, N (%) 85 (23.6%) 29 (26.4%) 45 (23.1%) 11 (20.0%) 0.641 
Race, N (%)     
   African-American  180 (50.0%) 54 (49.1%) 96 (49.2%) 30 (54.5%) 0.765 
   White  180 (50.0%) 56 (50.9%) 99 (50.8%) 25 (45.5%) 
Education, N (%)     
   High school/GED or less  109 (30.3%) 34 (30.9%) 59 (30.3%) 16 (29.1%) 0.841 
    Some college or 2 year degree  161 (44.7%) 50 (45.5%) 88 (45.1%) 23 (41.8%) 
   4 year college degree or greater  90 (25.0%) 26 (23.6%) 48 (24.6%) 16 (29.1%) 
Income, N (%)     
   <$20,000  103 (30.4%) 40 (37.4%) 51 (28.0%) 12 (24.0%) 0.383 
 
 
   $20,000-39,999  100 (29.5%) 26 (24.3%) 58 (31.9%) 16 (32.0%) 
   $40,000+  136 (40.1%) 41 (38.3%) 73 (40.1%) 22 (44.0%) 
Marital status, N (%)     
   Married/living with partner  164 (45.7%) 51 (46.4%) 90 (46.4%) 23 (41.8%) 0.823 
   Not married/living with partner 195 (54.3%) 59 (53.6%) 104 (53.6%) 32 (58.2%) 
Clinical 
Self-rated health, N (%)     
   Good or better  218 (60.6%) 46 (41.8%) 132 (67.7%) 40 (72.7%) <0.001 
    Fair or poor  142 (39.4%) 64 (58.2%) 63 (32.3%) 15 (27.3%) 
BMI, M (SD)  31.8 (6.5) 33.0 (7.1) 31.3 (6.2) 31.6 (6.4) 0.088 
WOMAC Total, M (SD)  48.0 (16.9) 54.5 (15.3) 45.7 (15.9) 42.7 (19.6) <0.001 
Charlson comorbidity, N (%)     
   0-1  104 (28.9%) 22 (20.0%) 70 (35.9%) 12 (21.8%) 0.017 
   2-3  121 (33.6%) 39 (35.5%) 60 (30.8%) 22 (40.0%) 
   4+  135 (37.5%) 49 (44.5%) 65 (33.3%) 21 (38.2%) 
Social & Psychological 
Social support, M (SD) 10.6 (3.9) 10.0 (3.9) 10.5 (3.8) 11.9 (3.9) 0.017 
Confidence filling out medical forms 
(health literacy item), n (%) 
     
   Adequate health literacy  284 (78.9) 83 (75.5) 153 (78.5) 48 (87.3) 0.210 
   Inadequate health literacy  76 (21.1) 27 (24.5) 42 (21.5) 7 (12.7) 
Depressive symptoms (PHQ-8), n (%)       
   None  140 (38.9%) 28 (25.5%) 87 (44.6%) 25 (45.5%) <0.001 
 
 
   Mild  118 (32.8%) 35 (31.8%) 61 (31.3%) 22 (40.0%) 
   Moderate to severe  102 (28.3%) 47 (42.7%) 47 (24.1%) 8 (14.5%) 
aWith or without other oral treatments 
bChi-squared/Fisher’s with categorical variables;  ANOVA with continuous variables 
 
Abbreviations: BMI, Body mass index; GED, General Educational Development; PHQ, Patient Health Questionnaire; WOMAC, 
Western Ontario & McMaster Universities Osteoarthritis Index 
 
Table 2.   Proportion of samples reporting use of oral analgesics for knee osteoarthritis 
Treatment group Treatment N (%) sample 
reporting use 
of specific 
treatment 
N (%) sample 
by treatment 
group 
No oral analgesic No oral analgesic  55 (15.3%) 55 (15.3%) 
Oral non-opioid analgesic Acetaminophen only 32 (8.9%) 195 (54.2%) 
Oral NSAIDsa only 111 (30.8%) 
Acetaminophen and oral 
NSAIDsa only  52 (14.4%) 
Oral opioid analgesic Opioids only 26 (7.2%) 110 (30.6%) 
Opioids with other oral 
analgesics 84 (23.3%) 
aIncluding cyclooxygenase-2 inhibitors 
 
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs 
 
 
  
 Table 3.  Social and psychological variables associated with oral analgesic use for knee osteoarthritis 
 Unadjusted a 
relative risk ratio 
(95% CI) 
p-value 
Adjusted b 
relative risk 
ratio 
(95% CI) p-value 
Fully Adjusted c 
relative risk 
ratio 
(95% CI) p-value 
Social support  
   Oral Non-Opioid Analgesic vs. No Oral Analgesic (Ref)   0.91 (0.83,0.99) 0.025 0.92 (0.84, 1.01) 0.085 0.94 (0.86,1.03) 0.188 
   Oral Opioid vs. No Oral Analgesic (Ref) 0.88 (0.80,0.96) 0.005 0.90 (0.82, 1.00) 0.044 0.92 (0.83,1.02) 0.120 
   Oral Opioid vs. Oral Non-Opioid Analgesic (Ref) 0.97 (0.91,1.03) 0.277 0.98 (0.92, 1.05) 0.519 0.98 (0.92,1.05) 0.601 
Adequate health literacy d 
   Oral Non-Opioid Analgesic vs. No Oral Analgesic (Ref)   0.53 (0.22,1.26) 0.151 0.46 (0.19, 1.13) 0.090 0.52 (0.21,1.30) 0.160 
   Oral Opioid vs. No Oral Analgesic (Ref) 0.45 (0.18,1.11) 0.082 0.45 (0.17, 1.18) 0.104 0.53 (0.20,1.42) 0.207 
   Oral Opioid vs. Oral Non-Opioid Analgesic (Ref) 0.84 (0.49,1.47) 0.547 0.97 (0.53, 1.79) 0.931 1.02 (0.55,1.89) 0.954 
Depression, moderate to severe e 
   Oral Non-Opioid Analgesic vs. No Oral Analgesic (Ref)   1.87 (0.82,4.23) 0.135 2.09 (0.80, 5.48) 0.133 1.93 (0.72,5.12) 0.189 
   Oral Opioid vs. No Oral Analgesic (Ref) 4.38 (1.89,10.15) 0.001 3.24 (1.20, 8.73) 0.020 2.96 (1.08,8.07) 0.035 
   Oral Opioid vs. Oral Non-Opioid Analgesic (Ref) 2.35 (1.42,3.87) 0.001 1.55 (0.88, 2.73) 0.131 1.53 (0.87,2.71) 0.140 
a Univariate multinomial model 
b Adjusted multinomial model adjusts for age, sex, race, income, WOMAC, comorbidity, and BMI. 
c Final multivariate multinomial model includes social support, health literacy, depression level, age, sex, race, income, WOMAC, comorbidity, and 
BMI. 
d vs. inadequate health literacy 
e vs. mild-no depression 
Abbreviations: BMI, Body mass index; WOMAC, Western Ontario & McMaster Universities Osteoarthritis Index 
  
FIGURE 
 
Figure 1.  Behavioral model for OA oral analgesic treatment use  
Abbreviations: OA, osteoarthritis; WOMAC, Western Ontario & McMaster Universities Osteoarthritis 
Index 
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SUPPLEMENTS 
 
Supplement 1. Study sample flow diagram 
*Numbers will not add to 351 because individuals could be ineligible for multiple reasons. 
**Scheduled for shot (n=1), knee pain due to an accident (n=1), difficulty completing screening survey 
(n=2) 
 
